New hope for arthritis patients: long-term safety trial launched
Disease control
Recruiting now
This study looks at the long-term safety and effectiveness of the drug TLL-018 in people with rheumatoid arthritis who have already finished a previous trial. About 350 adults aged 18 to 75 will take part. The goal is to see how well the drug controls arthritis symptoms over time…
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:28 UTC